NEW MATERIAL:A saccharide chain-modified interferon aggregate containing ≥85% of human interferon having a saccharide chain and not containing sialic acid at the non-reducing end of the saccharide chain.
USE: A remedy and diagnostic for hepatic diseases.
PREPARATION: For example, a human fibroblast is cultured and sufficiently multiplied to form a monolayer, which is treated with actinomycin, etc., to induce interferon. The supernatant of the culture solution is purified by a column chromatography method to separate interferon-β, which is dissolved in a 20mM acetic acid buffer solution (pH4.5) and treated with neuramidase at 37°C for 3 hours, followed by treating the product with a gel permeation column chromatography to remove free N-acetylneuraminic acid, thereby providing a saccharide-modified human interferon aggregate.
YAMAZAKI SHIYOUJIROU
SATO YUICHIRO
